Skip to main content
. 2020 Nov 20;23(2):299–317. doi: 10.1111/dom.14251

FIGURE 1.

FIGURE 1

SGLT‐2 inhibitors: clinical evidence across the renal disease continuum. C, CANVAS Program; CK, CREDENCE; D, DECLARE‐TIMI56; DK, DAPA‐CKD; E, EMPA‐REG OUTCOME; eGFR, estimated glomerular filtration rate; EK, EMPA‐Kidney; GFR, glomerular filtration rate